FDA approves Rasonque 6.5 months early, raising UAE pancreatic cancer access questions

The U.S. Food and Drug Administration (FDA) approved Rasonque (daraxonrasib) on 26 August 2026 for eligible adults with metastatic pancreatic adenocarcinoma, 6.5 months before the FDA goal date.

For UAE operators, the immediate issue is access. Dubai oncology clinics regulated by the Dubai Health Authority (DHA), Abu Dhabi and Al Ain providers regulated by the Department of Health Abu Dhabi (DOH), and northern emirates providers regulated by the Ministry of Health and Prevention (MOHAP) will need to treat this as a molecular testing, pharmacy sourcing and payer approval question before it becomes a routine pathway.

What the FDA approved

The FDA approval covers adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy. The dose listed by the FDA is 300 mg orally once daily until disease progression or unacceptable toxicity.

In the FDA-reviewed RASolute 302 trial, 500 adults were randomised to daraxonrasib or physician's choice of standard chemotherapy. Median overall survival was 13.2 months with daraxonrasib and 6.7 months with chemotherapy. Median progression-free survival was 7.2 months versus 3.6 months. Objective response rate was 30% versus 11%.

"This drug showed unprecedented results in an area of high unmet need," said Dr. Angelo de Claro, director of the FDA's Oncology Center of Excellence, in the FDA announcement.

The FDA said Rasonque received Breakthrough Therapy, Orphan Drug and Priority Review designations. The FDA approval notice is available here. The original regional news trigger was reported by Arabian Business.

Why UAE clinics and insurers should care

Rasonque is a targeted drug. That means UAE providers need a documented RAS mutation workflow before reimbursement discussions start. Medical directors should check whether pancreatic cancer panels already include RAS G12 reporting, turnaround time, tissue sufficiency rules and referral routes for repeat biopsy or liquid biopsy when tissue is limited.

For CFOs, the cost signal is material. Revolution Medicines disclosed a U.S. wholesale acquisition cost of $39,800 for a 30-day supply in an SEC filing. At the dollar-dirham peg, that is about AED 146,200 per month before UAE distributor margins, hospital mark-ups, VAT treatment, rebates or patient assistance. A six-month course at the U.S. list price implies about AED 877,000 before local contracting.

Insurers including Daman, Thiqa and Sukoon should expect early exceptional-approval requests rather than standard formulary traffic. The practical file will need four items:

• Histology confirming metastatic pancreatic adenocarcinoma.
• Prior systemic therapy record, or documentation that multiagent therapy is unsuitable.
• Molecular report showing the RAS result and testing method.
• Baseline toxicity plan for rash, diarrhoea, stomatitis, pneumonitis and gastrointestinal perforation risk.

What UAE operators should do next

MOHAP remains the national authority for pharmaceutical product registration and import oversight. An FDA approval does not itself create UAE market availability. Hospital pharmacies and private oncology centres should ask the manufacturer or local agent whether a UAE registration dossier has been filed, whether named-patient or special import routes are available, and what documentation MOHAP requires for unregistered oncology medicines.

Dubai providers should separate clinical readiness from commercial access. DHA-licensed clinics can prepare tumour board criteria, genetic testing templates and consent language now. Abu Dhabi and Al Ain providers should map the same pathway to DOH payer and facility rules. Northern emirates providers should confirm MOHAP and Emirates Health Services referral routes for cases that need tertiary oncology review.

The near-term bottleneck is unlikely to be physician awareness. It is more likely to be test availability, payer authorisation and drug supply timing. Operators should audit current pancreatic cancer patients against the FDA label within 30 days, then decide whether to pursue import access case by case. Patients and referring physicians can compare licensed oncology providers through the UAE Open Healthcare Directory.